Total Payments
$135,648
2024 Payments
$23,718
Companies
57
Transactions
522
Medicare Patients
975
Medicare Billing
$143,914
Payment Breakdown by Category
Other$82,061 (60.5%)
Consulting$34,075 (25.1%)
Food & Beverage$13,718 (10.1%)
Travel$4,884 (3.6%)
Research$776.00 (0.6%)
Education$134.53 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,061 | 21 | 58.3% |
| Consulting Fee | $34,075 | 34 | 25.1% |
| Food and Beverage | $13,718 | 440 | 10.1% |
| Travel and Lodging | $4,884 | 17 | 3.6% |
| Honoraria | $3,000 | 1 | 2.2% |
| Unspecified | $776.00 | 1 | 0.6% |
| Education | $134.53 | 8 | 0.1% |
Payments by Type
General
$134,872
521 transactions
Research
$776.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $87,449 | 117 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $19,233 | 55 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,801 | 14 | $0 (2018) |
| Lilly USA, LLC | $4,227 | 30 | $0 (2019) |
| Deciphera Pharmaceuticals Inc. | $3,806 | 6 | $0 (2024) |
| Exelixis Inc. | $2,083 | 7 | $0 (2019) |
| Celgene Corporation | $1,820 | 20 | $0 (2023) |
| Taiho Oncology, Inc. | $1,655 | 5 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,442 | 16 | $0 (2019) |
| Merck Sharp & Dohme LLC | $923.93 | 35 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,718 | 40 | E.R. Squibb & Sons, L.L.C. ($15,086) |
| 2023 | $17,487 | 24 | E.R. Squibb & Sons, L.L.C. ($16,583) |
| 2022 | $18,772 | 23 | E.R. Squibb & Sons, L.L.C. ($11,577) |
| 2021 | $13,041 | 16 | E.R. Squibb & Sons, L.L.C. ($12,764) |
| 2020 | $9,257 | 16 | E.R. Squibb & Sons, L.L.C. ($8,745) |
| 2019 | $16,472 | 36 | E.R. Squibb & Sons, L.L.C. ($10,972) |
| 2018 | $15,475 | 126 | Takeda Pharmaceuticals U.S.A., Inc. ($6,801) |
| 2017 | $21,426 | 241 | E.R. Squibb & Sons, L.L.C. ($7,849) |
All Payment Transactions
522 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | AUGTYRO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,278.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $115.89 | General |
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | AUGTYRO (Drug) | Travel and Lodging | Cash or cash equivalent | $804.46 | General |
| Category: Oncology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | AUGTYRO (Drug) | Food and Beverage | Cash or cash equivalent | $121.85 | General |
| Category: Oncology | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $3.11 | General |
| Category: Oncology | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $7.36 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: Oncology | ||||||
| 10/14/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $106.15 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,137.00 | General |
| Category: Oncology | ||||||
| 09/27/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $100.48 | General |
| Category: Oncology | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $5.05 | General |
| Category: Oncology | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $3.86 | General |
| Category: Oncology | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $244.62 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $13.09 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $244.62 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | Cash or cash equivalent | $41.86 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $39.81 | General |
| Category: Oncology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $13.09 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $122.07 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTREATED PATIENTS WITH EGFR MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $776.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 317 | 593 | $176,655 | $44,293 |
| 2022 | 6 | 251 | 560 | $167,176 | $42,335 |
| 2021 | 5 | 203 | 449 | $125,795 | $33,308 |
| 2020 | 6 | 204 | 363 | $103,291 | $23,978 |
Total Patients
975
Total Services
1,965
Medicare Billing
$143,914
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 101 | 271 | $77,608 | $19,162 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 49 | 121 | $34,684 | $8,380 | 24.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 65 | 66 | $25,440 | $6,671 | 26.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 55 | $18,787 | $4,820 | 25.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 49 | $10,960 | $2,946 | 26.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $6,277 | $1,672 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 15 | $2,899 | $641.18 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 83 | 284 | $81,024 | $20,076 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 114 | $32,584 | $8,085 | 24.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 53 | $15,774 | $4,215 | 26.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 33 | $12,885 | $3,476 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 38 | $7,799 | $2,120 | 27.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $6,879 | $1,782 | 25.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $5,853 | $1,420 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 11 | 11 | $4,378 | $1,162 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 76 | 244 | $68,320 | $17,812 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 53 | $14,840 | $4,126 | 27.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 37 | 39 | $14,859 | $3,979 | 26.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 66 | $13,266 | $3,705 | 27.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $8,430 | $2,363 | 28.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 32 | $6,080 | $1,324 | 21.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 174 | $51,156 | $10,426 | 20.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 37 | 75 | $15,000 | $4,340 | 28.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $10,008 | $2,933 | 29.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 42 | $12,348 | $2,384 | 19.3% |
About Dr. Moses Raj, MD
Dr. Moses Raj, MD is a Hematology & Oncology healthcare provider based in Denver, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1992707418.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Moses Raj, MD has received a total of $135,648 in payments from pharmaceutical and medical device companies, with $23,718 received in 2024. These payments were reported across 522 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,061).
As a Medicare-enrolled provider, Raj has provided services to 975 Medicare beneficiaries, totaling 1,965 services with total Medicare billing of $143,914. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Denver, NC
- Active Since 08/15/2005
- Last Updated 10/09/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992707418
Products in Payments
- OPDIVO (Biological) $71,599
- IMFINZI (Drug) $8,188
- IMFINZI (Biological) $8,138
- AUGTYRO (Drug) $7,204
- NINLARO (Drug) $6,768
- QINLOCK (Drug) $3,806
- ALIMTA (Drug) $2,654
- Cabometyx (Drug) $2,083
- CYRAMZA (Drug) $1,562
- Stivarga (Drug) $1,253
- TAGRISSO (Drug) $969.14
- KEYTRUDA (Biological) $731.29
- FLOWTRIEVER CATHETER, S (Device) $352.84
- Avastin (Biological) $274.85
- Lenvima (Drug) $194.82
- Photofrin (Drug) $190.96
- Intera 3000 Implantable Pump (Device) $162.14
- KRAZATI (Drug) $157.76
- LYNPARZA (Drug) $156.03
- Intera 3000 Hepatic Artery Infusion Pump (Device) $153.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Dr. Yousuf Gaffar, Md, MD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Robert Rifkin, Md, MD
Hematology & Oncology — Payments: $527,544
Hematology & Oncology $527,544
Dr. Jeffrey Matous, Md, MD
Hematology & Oncology — Payments: $357,552
Hematology & Oncology $357,552
Dr. Peter Mcsweeney, Md, MD
Hematology & Oncology — Payments: $151,717
Hematology & Oncology $151,717
Dr. Tara Gregory, M.d, M.D
Hematology & Oncology — Payments: $135,068
Hematology & Oncology $135,068
Peter Forsberg, Md, MD
Hematology & Oncology — Payments: $98,100
Hematology & Oncology $98,100